METHOD TO TREAT MAMMARY GLAND CANCER

medicine, oncology. SUBSTANCE: method deals with nonoperable patients and suggests to apply as a first treatment stage 4-7 injections paratumorally and into soft tissues at lymph outflow route using the following preparations, ml: 0.5%-richlocaine solution, 10; metotrexate, 5-10 mg; diclophenak solu...

Full description

Saved in:
Bibliographic Details
Main Authors BORDJUSHKOV JU.N, VLADIMIROVA L.JU, SIDORENKO JU.S, ZLATNIK E.JU, VERKHOVTSEVA A.I, ABRAMOVA N.A, MINDLIN S.S
Format Patent
LanguageEnglish
Published 20.01.2002
Edition7
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:medicine, oncology. SUBSTANCE: method deals with nonoperable patients and suggests to apply as a first treatment stage 4-7 injections paratumorally and into soft tissues at lymph outflow route using the following preparations, ml: 0.5%-richlocaine solution, 10; metotrexate, 5-10 mg; diclophenak solution/injection separately, 3; in a day, then at no intervals antitumor chemopreparations should be injected at standard course doses upon autoblood together with 50 mg richlocaine upon autoblood thrice weekly, separately, subsequently, for 2 wk, then the courses of autohemochemotherapy along with richlocaine injection should be repeated after a 2- week-long interval without any preliminary injection of preparations paratumorally and into soft tissues at lymph outflow route out of the mammary gland. EFFECT: higher efficiency of therapy, increased immunomodulating effect, improved chemotherapy tolerance due to decreased body toxic reactions, improved life quality in nonoperable patients at treating local and disseminated mammary gland cancer (III-IV stages) by cytostatic preparations. 3 ex, 8 tbl, 10 dwg
Bibliography:Application Number: RU20000106822